Sign in to view content

Two years visual acuity and anatomical outcomes of patients with diabetic macular oedema treated with intravitreal aflibercept in a real life setting

Marko Lukic, MD PhD FEBO FASRS

Video
Published 2019

Related

Outcomes of Patients with DME and Baseline BCVA 20/50 or Worse or 20/40 or Better Treated with Aflibercept 8 mg and 2 mg in the Phase 2/3 PHOTON Trial
Diana V Do, MD, FASRS
Updates from the Field
2024
Is It Necessary to Peel Internal Limiting Membrane in Diabetic Vitrectomy
Stanley Chang, MD
Updates from the Field
2022
Randomized Trial of PRP vs Intravitreal Ranibizumab Plus Deferred PRP for Proliferative Diabetic Retinopathy
Andrew N. Antoszyk, MD FASRS
Updates from the Field
2016

Category: Diabetic Retinopathy

See more